NOVO-AZITHROMYCIN PEDIATRIC POWDER FOR SUSPENSION
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
14-10-2016
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE)
Tillgänglig från:
TEVA CANADA LIMITED
ATC-kod:
J01FA10
INN (International namn):
AZITHROMYCIN
Dos:
200MG
Läkemedelsform:
POWDER FOR SUSPENSION
Sammansättning:
AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 200MG
Administreringssätt:
ORAL
Enheter i paketet:
15/22.5ML
Receptbelagda typ:
Prescription
Terapiområde:
OTHER MACROLIDES
Produktsammanfattning:
Active ingredient group (AIG) number: 0126072003; AHFS:
Bemyndigande status:
CANCELLED POST MARKET
Tillstånd datum:
2016-11-28
Produktens egenskaper
PRODUCT MONOGRAPH
PR
NOVO-AZITHROMYCIN
Azithromycin Tablets 250 mg
Azithromycin (as Azithromycin monohydrate hemiethanolate)
PR
NOVO-AZITHROMYCIN PEDIATRIC
Azithromycin Powder for Oral Suspension
100 mg*/5 mL and 200 mg*/ 5mL
*
Azithromycin (as Azithromycin monohydrate hemiethanolate)
ANTIBIOTIC
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Control No: 198791
Date of Revision:
October 07, 2016
_Novo-Azithromycin Product Monograph _
_ _
_Page 2 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
......................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
................................................................................................
5
WARNINGS AND PRECAUTIONS
...............................................................................
5
ADVERSE REACTIONS
..............................................................................................
10
DRUG
INTERACTIONS...............................................................................................
16
DOSAGE AND ADMINISTRATION
...........................................................................
20
OVERDOSAGE
............................................................................................................
25
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 25
STORAGE AND
STABILITY.......................................................................................
28
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 28
PART II: SCIENTIFIC INFORMATION
.............................................................................
30
PHARMACEUTICAL INFORMATION
.......................................................................
30
CLINICAL TRIALS
.........................................
Läs hela dokumentet
